Contribution: Innovation for Defence Excellence and Security Program - Innovation Networks
Oncovir Canada Inc
$2,099,792.00
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults
FY 2020-21 · 2021-03-16
Summary
Develop immunoassay kits that can measure all three classes of SARS-CoV-2 antibodies simultaneously or individually.
Department
Program
Innovation for Defence Excellence and Security Program - Innovation Networks
Recipient
Location
Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2023-12-29
Agreement Number
RD-003
Agreement Start Date
2021-03-16
Agreement Title
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults
Agreement Title (French)
Étude clinique sur l'innocuité et l'immunogénicité du poly-ICLC nasal (Hiltonol®) pour la prophylaxie du COVID-19 chez des adultes en bonne santé
Agreement Type
Contribution
Agreement Value
$2,099,792.00
Amendment Date
2023-04-14
Amendment Number
2
Description
Develop immunoassay kits that can measure all three classes of SARS-CoV-2 antibodies simultaneously or individually.
Description (French)
Développer des kits d'immun dosage capables de mesurer les trois classes d'anticorps anti-SRAS-CoV-2 simultanément ou individuellement.
Organization Code
dnd-mdn
Organization
National Defence | Défense nationale
Program Name
Innovation for Defence Excellence and Security Program - Innovation Networks
Program Name (French)
Programme d’innovation pour la défense, l’excellence et la sécurité - Réseaux d'innovation
Program Purpose
Collaborate with academic and private sector partners to build a network of expertise to support Canada’s current and future defence and security needs.
Program Purpose (French)
Collaborez avec des partenaires des secteurs universitaire et industriel afin de mettre en place un réseau d’expertise pour soutenir les besoins actuels et futurs du Canada en matière de défense et de sécurité.
Recipient City
Vancouver
Recipient Country
CA
Recipient Legal Name
Oncovir Canada Inc
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
018-2023-2024-Q1-RD-003
